Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids.
Plasma protein binding (PPB) methodology suitable for application in the lead optimisation of a corticosteroid series known to demonstrate non-specific binding (NSB) and poor solubility has been established. The method involved a modification to standard ultrafiltration (UF) techniques. In parallel with each experimental plasma sample, a control plasma sample was also processed by ultrafiltration. The retentate from experimental and control plasma samples were mixed back into the filtrate of the partner sample. The resulting regenerated plasma samples, one representing the experimental filtrate and one representing the experimental retentate, were then analysed by LC/MS/MS. Varying degrees of NSB were demonstrated with a number of corticosteroids, and this effect was eliminated using the modified method. Validation using a panel of established corticosteroids showed good agreement with published PPB figures. The published PPB figure for fluticasone propionate (FP) was, however, found to be an underestimate, and this was subsequently confirmed, at clinically relevant plasma concentrations, to be 99.3%. The modified method was particularly suited to lead optimisation because it provided samples in a consistent matrix compatible with standard high throughput LC/MS/MS analysis.
Taylor
Simon
S
riCEDD DMPK, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK. Simon.5.Taylor@GSK.com
Harker
Andy
A
D000305:Adrenal Cortex Hormones / Q000097:blood* / Q000737:chemistry; D000730:Androstadienes / Q000737:chemistry; D001798:Blood Proteins / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002853:Chromatography, Liquid / Q000379:methods; D000068298:Fluticasone; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods; D011485:Protein Binding; D011506:Proteins / Q000737:chemistry; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods; D014462:Ultrafiltration / Q000379:methods*
D000305:Adrenal Cortex Hormones; D000730:Androstadienes; D001798:Blood Proteins; D011506:Proteins; D000068298:Fluticasone